![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials
|
|
|
Reported by Jules Levin
AASLD 2014 Boston Nov 7-11
Massimo Puoti 1, Curti s Cooper2, Mark Sulkowski3, Graham R Foster4, Thomas Berg5, Erica Villa6, Federico Rodriguez-Perez7, Vinod Rustgi8, David Wyles9, Marti n King10, Barbara McGovern10, Heiner Wedemeyer11
1Ospedale Niguarda Ca Granda, Milan, Italy; 2University of Ott awa, Ott awa, Ontario, Canada; 3Johns Hopkins University, Balti more, Maryland, United States; 4Queen Mary University of London, Barts Health, London, United Kingdom; 5Universitätsklinikum Leipzig, Leipzig, Germany;
6AOU Policlinico di Modena, Modena, Italy; 7Gastroenterology and Hepati c Wellness Center, Santurce, Puerto Rico; 8University of Pitt sburgh Medical Center, Pitt sburgh, Pennsylvania, United States; 9University of California at San Diego, La Jolla, California, United States;
10AbbVie Inc., North Chicago, Illinois, United States; 11Medizinische Hochschule Hannover, Hannover, Germany
![AASLD1.gif](../images/111314/111314-1/AASLD1.gif)
![AASLD2.gif](../images/111314/111314-1/AASLD2.gif)
![AASLD3.gif](../images/111314/111314-1/AASLD3.gif)
![AASLD4.gif](../images/111314/111314-1/AASLD4.gif)
![AASLD5.gif](../images/111314/111314-1/AASLD5.gif)
![AASLD6.gif](../images/111314/111314-1/AASLD6.gif)
![AASLD7.gif](../images/111314/111314-1/AASLD7.gif)
![AASLD8.gif](../images/111314/111314-1/AASLD8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|